• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Owens & Minor Inc. filed SEC Form 8-K: Regulation FD Disclosure

    3/26/25 4:49:20 PM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email
    8-K
    OWENS & MINOR INC/VA/ VA false 0000075252 0000075252 2025-03-26 2025-03-26

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 26, 2025

     

     

    OWENS & MINOR, INC.

    (Exact name of Registrant as specified in charter)

     

     

     

    Virginia   001-09810   54-1701843
    (State or other jurisdiction
    of incorporation)
      (Commission
    file number)
      (I.R.S. employer
    identification no.)

     

    10900 Nuckols Road, Suite 400

    Glen Allen, Virginia

        23060
    (Address of principal executive offices)     (Zip code)

     

    Post Office Box 27626,
    Richmond, Virginia
        23261-7626
    (Mailing address of principal executive offices)     (Zip code)

    Registrant’s telephone number, including area code (804) 723-7000

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $2 par value per share   OMI   New York Stock Exchange

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 7.01.

    Regulation FD Disclosure.

    On March 26, 2025, Owens & Minor, Inc. (the “Company”) announced that it intends to offer and sell $600,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”) in a private offering (the “Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Offering is being conducted in connection with the financing of the Company’s previously announced proposed acquisition (the “Acquisition”) of Rotech Healthcare Holdings Inc. (“Rotech”). A copy of the press release announcing the Offering is furnished hereto as Exhibit 99.1.

    The Company is providing certain information in this current report on Form 8-K (this “Current Report”) with respect to Rotech and the Acquisition.

    The Notes are being offered only to persons reasonably believed to be “qualified institutional buyers,” as defined in and in accordance with Rule 144A under the Securities Act, and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. Accordingly, the Notes and the related guarantees will not be registered under the Securities Act or the securities laws of any other jurisdiction and the Notes and the related guarantees may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

    In connection with the Offering, the Company distributed the Management’s Discussion and Analysis of Financial Condition and Results of Operations of Rotech Healthcare Inc., a wholly owned subsidiary of Rotech (“RHI”) to potential investors, which is furnished hereto as Exhibit 99.2.

    Unless the Acquisition is consummated concurrently with or promptly following the closing of the Offering, the Company will deposit the gross proceeds from the Offering into a segregated escrow account until the date that certain escrow release conditions, including the consummation of the Acquisition, have been satisfied. The consummation of the Acquisition is subject to customary closing conditions. Upon the closing of the Offering or, if applicable, upon satisfaction of the escrow conditions, the Company intends to use the net proceeds of the Offering, together with cash on hand and expected borrowings under a new senior secured incremental term loan B facility to finance the consummation of the Acquisition and the other transactions contemplated by the merger agreement, including the repayment of Rotech debt and to pay Acquisition related fees and expenses. Any remaining net proceeds will be used for working capital and general corporate purposes.

    This Current Report is neither an offer to sell nor a solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Offering is not conditioned on the consummation of the Acquisition, which, if consummated, may occur subsequent to the closing of the Offering. This Current Report does not constitute a notice of repayment of outstanding indebtedness of Rotech. The terms and conditions of the new senior secured incremental term loan B facility have not been finalized and are therefore subject to change. The completion of the Offering is not conditioned upon our entering into the new senior secured incremental term loan B facility, and our entering into the new senior secured incremental term loan B facility is not conditioned upon the completion of the Offering.

    The information included in this Current Report under this Item 7.01 (including Exhibits 99.1 and 99.2), is being furnished to the U.S. Securities and Exchange Commission (the “SEC”) and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

     

    Item 8.01.

    Other Events.

    Included in this Current Report are (i) risk factors relating to the business of Rotech (Exhibit 99.3), (ii) a description and overview of Rotech’s business (Exhibit 99.4), (iii) unaudited pro forma condensed combined financial information of the Company giving effect to the Acquisition (the “Pro Forma Financial Information”), which includes the unaudited pro forma condensed combined balance sheet as of December 31, 2024 and the unaudited pro forma


    condensed combined statements of operations for the fiscal year ended December 31, 2024, and the notes related thereto (Exhibit 99.5), and (iv) the audited consolidated financial statements of RHI as of and for each of the years ended December 31, 2024 and 2023 and the notes related thereto and the related reports of RSM US LLP (“RSM”), RHI’s independent auditors (Exhibit 99.6).

    Also included in this Current Report is the consent of RSM, consenting to the incorporation by reference in certain of the Company’s registration statements of its report included in Exhibit 99.6 (Exhibit 23.1).

    The Pro Forma Financial Information included in this Current Report has been presented for informational purposes only and does not purport to indicate the results that actually would have been obtained had the Acquisition been completed on the assumed dates or for the periods presented, nor is it meant to be indicative of any anticipated combined financial position or future results of operations that the Company will experience after the Acquisition.

    Forward-Looking Statements

    This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations regarding the proposed Acquisition and the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words, including statements relating to the Acquisition, the Offering and the related financing for the Acquisition. The Company cautions readers of this communication that such “forward looking statements,” wherever they occur in this Current Report or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward-looking statements.”

    Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the inability to complete the proposed Acquisition due to the failure to satisfy other conditions to completion of the proposed Acquisition, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed Acquisition; risks related to disruption of management’s attention from the Company’s ongoing business operations due to the proposed Acquisition; the effect of the announcement of the proposed Acquisition on the Company’s relationships with its customers, suppliers and other third parties, as well as its operating results and business generally; the risk that the proposed Acquisition will not be consummated in a timely manner; exceeding the expected costs of the proposed Acquisition; the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected; the risk that the combined company may be unable to achieve expected synergies or that it may take longer than expected to achieve those synergies.

    Additional factors that could cause the Company’s actual outcomes or results to differ materially from those described in these forward-looking statements can be found in the “Risk Factors” sections of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in this Current Report and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.


    Item 9.01.

    Financial Statements and Exhibits

    (a) Financial Statements of Businesses Acquired.

    RHI’s audited consolidated financial statements as of and for each of the years ended December 31, 2024 and 2023 and the notes related thereto and the related reports of RSM, are incorporated by reference as Exhibit 99.6.

    (b) Pro Forma Financial Information.

    The Pro Forma Financial Information included in this Current Report, which includes the unaudited pro forma condensed combined statements of operations for the fiscal year ended December 31, 2024 and the unaudited pro forma condensed combined balance sheet as of December 31, 2024, and the notes related thereto are incorporated by reference as Exhibit 99.5.

    (d) Exhibits.

     

    23.1    Consent of RSM, RHI’s independent auditors.
    99.1    Press Release issued by the Company, dated March 26, 2025.
    99.2    Management’s Discussion and Analysis of Financial Condition and Results of Operations of RHI.
    99.3    Risks Related to Rotech.
    99.4    Overview of Rotech’s Business.
    99.5    Unaudited pro forma condensed combined financial information of the Company giving effect to the acquisition of Rotech, including the unaudited pro forma condensed combined statements of operations for the fiscal year ended December 31, 2024 and the unaudited pro forma condensed combined balance sheet as of December 31, 2024, and the notes related thereto.
    99.6    Historical audited consolidated financial statements and financial statement schedule of RHI as of and for each of the years ended December 31, 2024 and 2023, the notes related thereto and the related reports of RSM, RHI’s independent auditors.
    104    Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: March 26, 2025

     

    OWENS & MINOR, INC.
    By:  

    /s/ Heath Galloway

    Name:   Heath Galloway
    Title:   Executive Vice President, General Counsel and Corporate Secretary
    Get the next $OMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    11/3/2025$4.00Buy → Neutral
    UBS
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    More analyst ratings

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity

    The Transaction Includes the Owens & Minor Brand, and the Remaining Company Will Become Accendra Health Completes the Company's Transformation into a Pure Play Leader in the Home-Based Care Market Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc. "Today's announcement marks an inflection point in the strategic transformation of Owens & Minor into Accendra Health, a leading nationwide pure play home based care platform. The completion of the sale of the P&HS segment enables the Comp

    12/31/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.

    Accendra Health To Trade Under the "ACH" Symbol on the New York Stock Exchange Owens & Minor, Inc. (NYSE:OMI) ("the Company") today announced that it will change its name to Accendra Health, Inc. with an anticipated effective date of December 31, 2025. The name change affects only the name of the parent corporation and is intended to better reflect the Company's strategic direction and future organizational focus as a leader in the home-based care market. The Company will continue to use and operate under the Apria and Byram Healthcare brands. "The renaming of our organization is another milestone in the strategic transformation of our company as a leading, pure play home-based care busin

    12/18/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025

    Owens & Minor, Inc. (NYSE:OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company's President and Chief Executive Officer, and Will Parrish, the Company's Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and host one-on-one investor meetings at the conference in Miami, Florida. Please visit the "Events & Presentations" section of the "Investor Relations" page on the Owens & Minor website available at https://investors.owens-minor.com at least

    12/2/25 7:00:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    4/10/25 9:43:55 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    4/7/25 8:21:15 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    SEC Filings

    View All

    Amendment: Owens & Minor Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)

    1/5/26 4:05:19 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

    12/31/25 4:15:43 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

    12/18/25 4:18:47 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Owens & Minor downgraded by UBS with a new price target

    UBS downgraded Owens & Minor from Buy to Neutral and set a new price target of $4.00

    11/3/25 9:08:29 AM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor upgraded by Citigroup with a new price target

    Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

    7/19/24 7:41:01 AM ET
    $OMI
    Medical Specialities
    Health Care

    Leerink Partners initiated coverage on Owens & Minor with a new price target

    Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

    2/26/24 8:10:20 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CEO P&HS Long Andrew G gifted 47,908 shares, decreasing direct ownership by 18% to 214,064 units (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    11/20/25 4:11:13 PM ET
    $OMI
    Medical Specialities
    Health Care

    EVP & CFO Leon Jonathan A covered exercise/tax liability with 4,265 shares, decreasing direct ownership by 2% to 218,522 units (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    9/24/25 4:07:31 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    11/12/24 10:32:12 AM ET
    $OMI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    2/13/24 5:12:07 PM ET
    $OMI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    2/12/24 5:29:41 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

    Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

    6/22/22 6:50:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Financials

    Live finance-specific insights

    View All

    Owens & Minor Reports Third Quarter 2025 Financial Results

    Signed Definitive Agreement for the Sale of Products & Healthcare Services Segment Transaction Positions the Company as a Pure-Play Home-Based Care Business Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. "Our recent announcement on the sale of our Products & Healthcare Services segment is another meaningful step in our strategy to pivot our focus to the more attractive home-based care space. We are keenly focused on reshaping ou

    10/30/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Date and Time Change of Third Quarter 2025 Financial Results and Conference Call

    Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the third quarter of 2025 on Thursday, October 30, 2025, after trading ends on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 5:00 p.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast c

    10/16/25 6:30:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment to Platinum Equity for $375mm in Cash and a Retained Equity Stake

    Transforms Owens & Minor into a Pure Play Market Leader in the Home-Based Care Market 5% Retained Equity Stake Provides Ability to Realize Future Value Creation Under Platinum Equity Preserves Tax Attributes in Excess of $150 Million Owens & Minor, Inc. (NYSE:OMI) today announced that it has entered into a definitive agreement for the sale of the Company's Products & Healthcare Services (P&HS) segment to Platinum Equity. Over the last several years, Owens & Minor has been strategically moving towards expanding its leadership position in the very attractive home-based care space. This transaction will allow the Company to focus on a simpler business model and allow for a more appropria

    10/7/25 4:15:00 PM ET
    $OMI
    Medical Specialities
    Health Care